advertisement
Abstract #8790 Published in IGR 5-1
Oral citicoline treatment improves visual pathway function in glaucoma
Rejdak R; Toczolowski J; Krukowski J; Kaminski M; Rejdak K; Stelmasiak Z; Grieb PMedical Science Monitor 2003; 9: PI24-PI28
BACKGROUND: Increased latency and reduced amplitude of visual evoked potentials (VEP), frequently encountered in ocular hypertension or open-angle glaucoma, suggest slowed neural conduction in the visual pathways. An improvement in VEP latency and amplitude has been reported following repeated intramuscular injections of citicoline, a neuroprotective drug. The authors' aim was to discover whether citicoline given orally would produce a similar eftect. MATERIAL AND METHODS: VEP latency and amplitude were measured in 21 glaucomatous eyes prior to and after two bi-weekly courses of citicoline taken orally in a dose of 1 g/day. The treatment courses were separated by a two-week break; post-treatment VEP measurement was performed two weeks after the end of the second treatment. RESULTS: Sixty-two percent of the eyes showed a response to the treatment, with VEP latency reduced from 123.5 (3.9 SEM) to 111.9 msec (p = 0.0008), and VEP amplitude increased from 6.56 (1.39 SEM) to 7.88 (1.16 SEM) (p = 0.04). CONCLUSION: Citicoline given orally improves visual evoked potentials in some glaucoma patients.
Dr. P. Grieb, Laboratory of Experimental Pharmacology, Polish Acad. of Science Medical Research Center, Pawinskiego 5, 02-106 Warszawa, Poland. pgrieb@cmdik.pan.pl
Classification:
11.8 Neuroprotection (Part of: 11 Medical treatment)
